Liposarcomas are uncommon in the pediatric population. We present the case of a boy who had experienced multiple recurrences of liposarcoma in the buccal space before he reached the age of 13 years. We also provide a review of the literature and a discussion of adjuvant therapy, which are important to understanding the nature of this disease.
Introduction
Liposarcoma is a relatively common soft -tissue tumor in adults, but it is rare in the pediatric population. It is most commonly located in the lower extremities and retroperitoneum; tumors of the head and neck region are rather uncommon. Intraoral liposarcomas account for only 5 to 8% of all head and neck sarcomas. 1 Liposarcomas are slightly more common in men than in women.
Enzinger and Weiss classifi ed liposarcomas according to histology, identifying fi ve subtypes: well-diff erentiated, myxoid, round-cell, dediff erentiated, and pleomorphic. 2 Th e most common subtype is the myxoid variant. In this article, we describe an unusual case of recurrent myxoid liposarcoma of the buccal mucosa, and we review the relevant literature.
Case report
A 9-year-old boy initially presented to another institution with a progressive swelling of his left cheek. On examination, he was noted to have a fi rm, 3.0 × 2.5 × 2.0-cm mass centered in the left buccal mucosa. Th e mass was resected with negative surgical margins at this institution. Th e pathology report identifi ed a tissue capsule surrounding gelatinous, myxoid, lobulated tissue, which was thought to be consistent with a benign lipoblastoma.
Postoperatively, the patient did well for approximately 2 years, but he eventually noticed a recurrence of the swelling in the same area of his left cheek. He returned to the same outside institution, where examination revealed a fullness of the left buccal mucosa and the presence of a palpable, mobile, tender mass. On magnetic resonance imaging (MRI), the mass measured approximately 3.0 × 2.0 cm. Th e recurrent mass was resected with negative surgical margins. Pathology results were again considered to be consistent with a benign lipoblastoma.
Th e patient recovered well postoperatively, but he experienced another swelling in the left cheek approximately 1 year later. He was then referred to the Department of Otorhinolaryngology-Head and Neck Surgery at the University of Maryland School of Medicine in Baltimore. As before, he was taken to surgery for resection of the mass. However, this time the results of the pathology examination yielded a diagnosis of a well-diff erentiated myxoid liposarcoma. Given this unsuspected fi nding, we reviewed the pathologic specimen removed from the previous surgery (slides from the fi rst surgery were not available), and it exhibited similar tumor histology; in retrospect it, too, was identifi ed as a myxoid liposarcoma (fi gure 1). risk of local recurrence. Th e patient underwent CTbased planning, and intensity-modulated radiotherapy was administered to minimize the size of the dose to nearby normal tissues. He received a total dose of 59.4 Gy in 33 daily fractions of 1.8 Gy each. He experienced no delays in treatment due to toxicity, and he tolerated his radiotherapy well.
At 55 months since the completion of his adjuvant radiotherapy, the patient has shown no clinical or radiographic evidence of disease recurrence. He has had some side eff ects from his multiple surgeries and radiation therapy, including long-term xerostomia and signifi cant trismus. He has undergone two additional facial reconstructive surgeries, including one to help relieve his trismus.
Discussion
To the best of our knowledge, only 35 cases of liposarcoma of the cheek or buccal mucosa have been previously reported in the literature. (In some of those reports, the distinction between cheek and buccal mucosa tumors was not entirely clear.) Compared with all the patients in the previously reported cases, our patient was the youngest with a primary tumor of the buccal mucosa.
Before his diagnosis of myxoid liposarcoma, our patient had twice been diagnosed as having a lipoblastoma. Lipoblastomas are benign tumors of childhood, but they are histologically very similar to myxoid liposarcomas, and the two can be easily confused with each other. 3 Th us, the possibility exists that our patient's initial mass was misdiagnosed. Indeed, his fi rst recurrence 2 years later was in retrospect a myxoid liposarcoma, not a lipoblastoma. On the other hand, it is possible that he did indeed Because the status of the resection margins aft er the most recent surgery was unclear, the patient underwent a revision resection 3 months later. Pathologic review of the re-excised specimen detected rare microscopic foci of residual myxoid liposarcoma measuring up to 2 mm; all surgical margins were free of tumor. Postoperatively, the patient underwent a temporalis fl ap reconstruction.
Eleven months later, at which time the patient was 13 years old, he was noted on surveillance MRI to have a mass in the left retromaxillary area, with extension medially toward the pterygomaxillary fi ssure, laterally beneath the zygoma, superiorly to the temporal fossa, and inferiorly to the level of the maxillary alveolar ridge. Positron-emission tomography/computed tomography (PET/CT) revealed an increased uptake in this area consistent with a local recurrence (fi gure 2). No evidence of metastatic disease was noted.
Th e patient subsequently underwent his fi ft h surgery, which involved a lateral rhinotomy, excision of the infratemporal fossa liposarcoma, and wide local excision of an extradural anterior skull base lesion. Pathologic review was again consistent with a recurrent myxoid liposarcoma of the left infratemporal fossa, with the closest margin being less than 1 mm. Th e tumor had involved the maxillary tuberosity, posterior buccal space, and buccal fat. All other tissues and margins were negative for tumor. Following surgery, the patient experienced a number of postoperative side eff ects, including blurred vision in the left eye and trismus.
In view of the persistently recurrent nature of the tumor and the close surgical margins near the base of the skull, postoperative radiation therapy to the tumor bed was recommended in order to decrease the patient's have an initial benign lipoblastoma that subsequently underwent malignant transformation. Liposarcoma characteristics. While benign lipoblastomas are the most common adipocytic tumors of childhood, liposarcomas are uncommon in the pediatric population. In a 1983 report, Shmookler and Enzinger found only 17 cases of childhood liposarcoma, which accounted for less than 1% of all liposarcomas in the Armed Forces Institute of Pathology database. 4 Th e most common site in these children was the lower extremity, and the most common subtype was myxoid (76%). All of those patients had undergone surgical excision, and 2 received postoperative radiotherapy.
Patients with myxoid, well-diff erentiated, or low-grade liposarcomas have an excellent prognosis. No cases of metastatic myxoid liposarcoma have been reported in children. 5 Although metastasis is unlikely, local recurrence is common, with recurrence rates for myxoid liposarcomas ranging from 33 to 53%. 6, 7 In addition to histologic subtype, important factors in predicting 5-year survival among young patients are the completeness of resection, the location of the tumor (extremity vs. nonextremity), and the tumor size (≤5 cm vs. >5 cm), according to a report by La Quaglia et al. 8 Th ese prognostic factors are consistent with data for the adult population.
Head and neck lesions constitute less than 1% of all liposarcomas, and oral and salivary gland tumors account for 0.3% of all cases. 1, 9 Th e most common subsites of intraoral liposarcomas are the cheek and tongue. 10, 11 Among intraoral liposarcomas, the prevailing histologic subtypes are myxoid and well-diff erentiated; there is disagreement over which is more common. [9] [10] [11] [12] All subtypes have been reported in the literature. 13, 14 Myxoid and well-diff erentiated liposarcomas are low-grade tumors, and even when they are located in the head and neck region, patients generally have a rather favorable prognosis. 6, 7 In one series, however, Golledge et al found that patients with an oral liposarcoma had a poor prognosis, with a 5-year survival of 50%. 1 Treatment. Th e preferred management of myxoid liposarcoma, irrespective of location, has remained unchanged over the years; surgical resection with wide margins has long been held as the standard. 15 As mentioned, however, even in cases of pathologically negative margins, local recurrence is common. For liposarcomas of the cheek and buccal mucosa, wide local excision poses a surgical challenge in view of the tumor's proximity to and involvement with neurovascular and other critical anatomic structures.
Th e roles of neoadjuvant and adjuvant treatments for liposarcoma are less clear. It is generally accepted that adjuvant radiotherapy improves local control but not overall survival. It is also generally accepted that adjuvant radiotherapy is indicated in the setting of microscopic residual disease following maximal resection, although some investigators have questioned the benefi ts of adjuvant radiotherapy. 1, 9 Th e use of external-beam radiotherapy for the treatment of head and neck liposarcoma has been reported. Radiation has been used to treat both primary and recurrent liposarcomas of the cheek and buccal mucosa (table). Nikitakis et al used radiotherapy as an adjuvant treatment in patients with close resection margins. 16 Eidinger et al used radiotherapy routinely because of poor local control with surgery alone. 17 Radiotherapy was used in our patient because of the multiply recurrent nature of his tumor, its proximity to critical structures, and our concern that future surgical salvage of another local recurrence would be challenging, if not impossible, in the context of his previous surgeries.
Of all the patients described in the literature who had received adjuvant radiotherapy, only 1 experienced a local recurrence; of note, this patient received 60 Gy. 17 In a retrospective study of 18 younger patients (≤22 yr), La Quaglia et al noted the use of adjuvant radiotherapy in 3 patients who had microscopic residual disease aft er resection; 2 of these patients experienced long-term disease-free survival, leading the authors to conclude 
. PET/CT demonstrates the lesion (arrows) within the left retromaxillary area (A) with extension into the suprazygomatic masticator space (B).
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that with positive microscopic margins, aggressive resection combined with radiotherapy can achieve good local control. 8 No randomized controlled trials looking specifi cally at the benefi t of adjuvant radiotherapy in patients with liposarcoma have been published. Hence, we have only retrospective reviews to guide treatment recommendations. In 1954, Pack and Pierson reported a greater 5-year survival with surgery and radiotherapy (88%) over surgery alone (67%). 18 Since then, however, some others have found diff erent outcomes. For example, in a case series of head and neck liposarcomas published in 1995, Golledge et al found that 5-year survival was higher aft er surgery alone compared with surgery plus adjuvant radiotherapy-83 and 63%, respectively. 1 In that series, however, 75% of patients who had undergone adjuvant radiotherapy had unfavorable histologic fi ndings (i.e., pleomorphic or round-cell subtypes), a variable that highlights the selection bias inherent in such studies. In a similar series, Wanebo et al also found no overall survival advantage for patients who received adjuvant radiotherapy, but again, this might have been attributable to selection bias. 19 Other series seem to confi rm the observation that radiotherapy does not improve overall survival in liposarcoma patients, but it does lower the local recur-rence rate. For example, Eeles et al showed that adjuvant radiotherapy in head and neck sarcomas lowered local recurrence rates by 20%. 20 Likewise, Evans found a decrease in local recurrence in patients with myxoid liposarcoma who had been treated with adjuvant radiotherapy. 21 Local control is especially critical for patients who have already had recurrent disease. Because our patient was so young, adjuvant radiotherapy was initially deferred in view of his negative margins and our desire to limit his risk of long-term side eff ects. However, it can be argued that any patient who develops a liposarcoma at these sites is a candidate for adjuvant radiotherapy, especially when wide negative margins cannot be obtained.
Th e role of preoperative treatment remains unclear. We found 1 case in the literature of neoadjuvant radiotherapy for an intraoral liposarcoma. 22 Th e patient was a 16-yearold boy who was found to have a cheek liposarcoma. He underwent preoperative radiation therapy to an unspecifi ed dose followed by wide surgical excision with no evidence of local recurrence. Wong et al reported the use of preoperative radiotherapy in a myxoid liposarcoma of the chest wall; radiotherapy was initiated in that case because of the proximity of the tumor to neurovascular bundles and bone and because wide surgical margins were not expected to be obtained. 23 Yamaguchi et al re- ported the use of preoperative radiotherapy in oral and maxillofacial sarcomas, with doses ranging from 18 to 80 Gy. 15 Th us, there might still be a role for neoadjuvant radiotherapy in liposarcomas of the cheek and buccal mucosa in unique cases in which cytoreduction of the tumor would improve resectability. Th e local control benefi ts associated with adjuvant radiotherapy must be weighed against its associated acute and chronic side eff ects in the context of the patient's age and site of treatment. Radiotherapy can facilitate greater organ preservation and less long-term morbidity in patients who are at higher risk of local failure.
In conclusion, surgery combined with adjuvant radiotherapy should be considered as the primary treatment for recurrent liposarcomas of the cheek and buccal mucosa.
